You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,833,525


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,833,525
Title:Crystals of whole antibodies and fragments thereof and methods for making and using them
Abstract: This invention relates to crystals of whole antibodies and fragments thereof, and formulations and compositions comprising such crystals. More particularly, methods are provided for the crystallization of high concentrations of whole antibodies, and fragments thereof, in large batches, and for the preparation of stabilized whole antibody crystals for use alone, or in dry or slurry formulations or compositions. This invention also relates to methods for stabilization, storage and delivery of biologically active whole antibody crystals.
Inventor(s): Shenoy; Bhami (Woburn, MA), Govardhan; Chandrika P. (Lexington, MA), Yang; Mark X. (Newton, MA), Margolin; Alexey L. (Newton, MA)
Assignee:
Application Number:10/034,950
Patent Claims:1. A crystal of infliximab, wherein the crystal comprises infliximab, ethoxyethanol, lithium sulfate, and Tris buffer.

2. The crystal of claim 1, wherein the pH of the Tris buffer is 8.6.

3. A method of crystallizing infliximab, the method comprising: combining infliximab, ethoxyethanol, lithium sulfate, and Tris buffer, thereby forming a crystallization solution; and incubating the crystallization solution, thereby crystallizing infliximab.

4. The method of claim 3, wherein the method is performed at room temperature.

5. The method of claim 3, wherein the method is performed at pH 8.6.

6. The method of claim 3, wherein the concentration of infliximab in the crystallization solution is .times. ##EQU00001##

7. The method of claim 3, wherein the percentage of ethoxyethanol in the crystallization solution is .times..times. ##EQU00002##

8. The method of claim 3, wherein the concentration of lithium sulfate in the crystallization solution is .times. ##EQU00003##

9. The method of claim 3, wherein the concentration of Tris buffer in the crystallization solution is .times. ##EQU00004##

10. The method of claim 3, wherein the concentration of infliximab in the crystallization solution is .times..times. ##EQU00005## the percentage of ethoxyethanol in the crystallization solution is .times. ##EQU00006## the concentration of lithium sulfate in the crystallization solution is .times..times. ##EQU00007## and the concentration of Tris buffer in the crystallization solution is .times..times. ##EQU00008##

11. A crystal of infliximab, wherein the crystal comprises infliximab, PEG-400, lithium sulfate, and Tris buffer.

12. The crystal of claim 11, wherein the pH of the Tris buffer is 8.5.

13. A method of crystallizing infliximab, the method comprising: combining infliximab, PEG-400, lithium sulfate, and Tris buffer, thereby forming a crystallization solution; and incubating the crystallization solution, thereby crystallizing infliximab.

14. The method of claim 13, wherein the method is performed at room temperature.

15. The method of claim 13, wherein the method is performed at pH 8.5.

16. The method of claim 13, wherein the concentration of infliximab in the crystallization solution is .times..times. ##EQU00009##

17. The method of claim 13, wherein the percentage of PEG-400 in the crystallization solution is .times..times. ##EQU00010##

18. The method of claim 13, wherein the concentration of lithium sulfate in the crystallization solution is .times..times. ##EQU00011##

19. The method of claim 13, wherein the concentration of Tris buffer in the crystallization solution is .times..times. ##EQU00012##

20. The method of claim 13, wherein the concentration of infliximab in the crystallization solution is .times..times. ##EQU00013## the percentage of PEG-400 in the crystallization solution is .times..times. ##EQU00014## the concentration of lithium sulfate in the crystallization solution is .times..times. ##EQU00015## and the concentration of Tris buffer in the crystallization solution is .times..times. ##EQU00016##

21. A crystal of infliximab, wherein the crystal comprises infliximab, polyethylene glycol monomethyl ether 550 (PEG MME 550), calcium chloride, and Tris HCl buffer.

22. The crystal of claim 21, wherein the pH of the Tris HCl buffer is 7.0.

23. A method of crystallizing infliximab, the method comprising: combining infliximab, PEG MME 550, calcium chloride, and Tris HCl buffer, thereby forming a crystallization solution; and incubating the crystallization solution, thereby crystallizing infliximab.

24. The method of claim 23, wherein the method is performed at room temperature.

25. The method of claim 23, wherein the pH of the Tris HCl buffer is 7.0.

26. The method of claim 23, wherein the concentration of infliximab in the crystallization solution is .times..times. ##EQU00017##

27. The method of claim 23, wherein the percentage of PEG MME 550 in the crystallization solution is .times..times. ##EQU00018##

28. The method of claim 23, wherein the concentration of calcium chloride in the crystallization solution is .times..times. ##EQU00019##

29. The method of claim 23, wherein the concentration of Tris HCl buffer in the crystallization solution is .times..times. ##EQU00020##

30. The method of claim 23, wherein the concentration of infliximab in the crystallization solution is .times..times. ##EQU00021## the percentage of PEG MME 550 in the crystallization solution is .times. ##EQU00022## the concentration of calcium chloride in the crystallization solution is .times..times. ##EQU00023## and the concentration of Tris HCl buffer in the crystallization solution is .times..times. ##EQU00024##

31. A crystal of infliximab, wherein the crystal comprises infliximab, PEG 300, Tris buffer, PEG 8000, and glycerol.

32. The crystal of claim 31, wherein the pH of the Tris buffer is 8.5.

33. A method of crystallizing infliximab, the method comprising: combining infliximab, PEG 300, Tris buffer, PEG 8000, and glycerol, thereby forming a crystallization solution; and incubating the crystallization solution, thereby crystallizing infliximab.

34. The method of claim 33, wherein the method is performed at room temperature.

35. The method of claim 33, wherein the pH is 8.5.

36. The method of claim 33, wherein the concentration of infliximab in the crystallization solution is .times..times. ##EQU00025##

37. The method of claim 33, wherein the percentage of PEG 300 in the crystallization solution is .times. ##EQU00026##

38. The method of claim 33, wherein the concentration of Tris buffer in the crystallization solution is .times..times. ##EQU00027##

39. The method of claim 33, wherein the percentage of PEG 8000 in the crystallization solution is .times. ##EQU00028##

40. The method of claim 33, wherein the percentage of glycerol in the crystallization solution is .times. ##EQU00029##

41. The method of claim 33, wherein the concentration of infliximab in the crystallization solution is .times..times. ##EQU00030## the percentage of PEG 300 in the crystallization solution is .times. ##EQU00031## the concentration of Tris buffer in the crystallization solution is .times..times. ##EQU00032## the percentage of PEG 8000 in the crystallization solution is .times. ##EQU00033## and the percentage of glycerol in the crystallization solution is .times. ##EQU00034##

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.